<DOC>
	<DOCNO>NCT01221519</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability measure extent rate absorption different tablet formulation AZD1656 T2DM patient .</brief_summary>
	<brief_title>A Relative Bioavailability Study Measuring Extent Rate Absorption Different Tablet Formulations AZD1656 Type 2 Diabetes Mellitus ( T2DM ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure . Males females nonchildbearing potential ( postmenopausal , and/or undergone hysterectomy and/or bilateral oophorectomy salpingectomy/ tubal ligation ) age ≥18 year . Females define postmenopausal last menstruation period &gt; 1 year ago serum follicle stimulate hormone ( FSH ) within postmenopausal range , age &gt; 50 year last menstruation period &gt; 2 year ago . A confirm clinical diagnosis T2DM least 1 year , treat metformin single treatment combination one oral antidiabetic ( ie , DPPIV inhibitor SU ) least 2 month prior screen . Doses antidiabetic treatment stable least 1 month prior screen . Treatment least 1000mg Metformin 2 month stable Metformin Therapy 1 month Hb A1c &gt; 6.5 % ( international standard ) enrolment . Body mass index ( BMI ) ≥19 ≤42 kg/m2 . Clinically significant illness clinically relevant trauma , judge Investigator , within 2 week prior first administration AZD1656 Participation another clinical study 30 day prior screen intake another investigational drug within 30 day ( least 5 x t1/2 drug ) prior first administration AZD1656 . History , ongoing , ischemic heart disease heart failure . Stroke , transitory ischemic attack , symptomatic peripheral arterial disease within last 6 month . Clinically significant abnormality ECG , clinical chemistry , hematology urinalysis result . Positive test Hepatitis B surface antigen ( HBsAg ) antibodies human immunodeficiency virus ( HIV ) Hepatitis C virus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Diabetic treatment</keyword>
	<keyword>Metformin</keyword>
	<keyword>High blood sugar</keyword>
</DOC>